Revvity (RVTY) Current Deferred Revenue (2014 - 2016)
Revvity's (RVTY) quarterly Current Deferred Revenue came in at $163.2 million in Q1 2016, down 3.41% on a YoY basis from $168.9 million in Q1 2015, and down 3.41% quarter-over-quarter from $168.9 million in Q4 2014.
Powered by 
Analysis
Revvity (RVTY) Current Deferred Revenue (2014 - 2016) Analysis & Trends
Revvity (RVTY) has reported Current Deferred Revenue for 2 consecutive years, with $163.2 million the latest figure, recorded in Q1 2016.
- For the quarter ending Q1 2016, Current Deferred Revenue fell 3.41% year-over-year to $163.2 million; the trailing twelve-month figure through Jan 2016 stood at $163.2 million (down 3.41% YoY), and the FY2016 full-year result was $163.2 million, down 3.41% from the prior year.
- Current Deferred Revenue fell to $163.2 million in Q1 2016 per RVTY's latest filing, from $168.9 million in the prior quarter.
- Across five years, Current Deferred Revenue topped out at $168.9 million in Q4 2014 and bottomed at $163.2 million in Q1 2016.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Thermo Fisher Scientific | 241.68 Bn | 237.61 Bn | 8.34 Bn |
| 2 | Danaher | 147.34 Bn | 142.99 Bn | 3.61 Bn |
| 3 | Agilent Technologies | 43.34 Bn | 41.59 Bn | 1.04 Bn |
| 4 | Illumina | 34.58 Bn | 33.41 Bn | 770.00 Mn |
| 5 | Revvity | 16.31 Bn | 15.29 Bn | 416.87 Mn |
| 6 | Bio-Techne | 11.28 Bn | 11.01 Bn | 211.39 Mn |
| 7 | Bio-Rad Laboratories | 10.16 Bn | 8.54 Bn | 345.80 Mn |
| 8 | Repligen | 9.77 Bn | 8.75 Bn | 110.04 Mn |
| 9 | 10x Genomics | 9.45 Bn | 8.90 Bn | 112.50 Mn |
| 10 | Bruker | 9.26 Bn | 9.04 Bn | 416.00 Mn |